Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.

Kong FM, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, Ramnath N, Hassan KA, Matuszak M, Ritter T, Bi N, Wang W, Orringer M, Cease KB, Lawrence TS, Kalemkerian GP.

JAMA Oncol. 2017 Oct 1;3(10):1358-1365. doi: 10.1001/jamaoncol.2017.0982.

2.

Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen.

Oscherwitz J, Quinn CP, Cease KB.

Vaccine. 2015 May 11;33(20):2342-6. doi: 10.1016/j.vaccine.2015.03.037. Epub 2015 Mar 26.

3.

Identification and validation of a linear protective neutralizing epitope in the β-pore domain of alpha toxin.

Oscherwitz J, Cease KB.

PLoS One. 2015 Jan 30;10(1):e0116882. doi: 10.1371/journal.pone.0116882. eCollection 2015.

4.

Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.

Oscherwitz J, Feldman D, Yu F, Cease KB.

Vaccine. 2015 Jan 9;33(3):430-6. doi: 10.1016/j.vaccine.2014.11.042. Epub 2014 Nov 30.

5.

In vivo mapping of a protective linear neutralizing epitope at the N-terminus of alpha hemolysin from Staphylococcus aureus.

Oscherwitz J, Muñoz-Planillo R, Yu F, Núñez G, Cease KB.

Mol Immunol. 2014 Jul;60(1):62-71. doi: 10.1016/j.molimm.2014.03.012. Epub 2014 Apr 24.

PMID:
24769493
6.

Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy.

Yuan ST, Brown RK, Zhao L, ten Haken RK, Gross M, Cease KB, Schipper M, Stanton P, Yu J, Kong FM.

Radiat Oncol. 2014 Jan 27;9(1):37. doi: 10.1186/1748-717X-9-37.

7.

Staphylococcus δ-toxin induces allergic skin disease by activating mast cells.

Nakamura Y, Oscherwitz J, Cease KB, Chan SM, Muñoz-Planillo R, Hasegawa M, Villaruz AE, Cheung GY, McGavin MJ, Travers JB, Otto M, Inohara N, Núñez G.

Nature. 2013 Nov 21;503(7476):397-401. doi: 10.1038/nature12655. Epub 2013 Oct 30.

8.

A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.

Ramnath N, Daignault-Newton S, Dy GK, Muindi JR, Adjei A, Elingrod VL, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Troeschel S, Johnson CS, Trump DL.

Cancer Chemother Pharmacol. 2013 May;71(5):1173-82. doi: 10.1007/s00280-013-2109-x. Epub 2013 Feb 23.

9.

Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.

Oscherwitz J, Yu F, Jacobs JL, Cease KB.

Clin Vaccine Immunol. 2013 Mar;20(3):341-9. doi: 10.1128/CVI.00612-12. Epub 2013 Jan 2.

10.

Cancer Carepartners: Improving patients' symptom management by engaging informal caregivers.

Silveira MJ, Given CW, Cease KB, Sikorskii A, Given B, Northouse LL, Piette JD.

BMC Palliat Care. 2011 Nov 25;10:21. doi: 10.1186/1472-684X-10-21.

11.

A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax.

Oscherwitz J, Yu F, Cease KB.

J Immunol. 2010 Sep 15;185(6):3661-8. doi: 10.4049/jimmunol.1001749. Epub 2010 Aug 9.

12.

A CD20 tandem-epitope immunogen elicits antibody in mice that binds murine cell surface CD20 and depletes splenic B cells in vivo.

Oscherwitz J, Gribbin TE, Cease KB.

Mol Immunol. 2010 Apr;47(7-8):1484-91. doi: 10.1016/j.molimm.2010.01.026. Epub 2010 Feb 26.

PMID:
20189250
14.

Comparative survival in patients with postresection recurrent versus newly diagnosed non-small-cell lung cancer treated with radiotherapy.

Cai XW, Xu LY, Wang L, Hayman JA, Chang AC, Pickens A, Cease KB, Orringer MB, Kong FM.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1100-5. doi: 10.1016/j.ijrobp.2009.03.017. Epub 2009 Jun 18.

PMID:
19540063
15.

Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen.

Oscherwitz J, Yu F, Jacobs JL, Liu TH, Johnson PR, Cease KB.

Infect Immun. 2009 Aug;77(8):3380-8. doi: 10.1128/IAI.00358-09. Epub 2009 Jun 1.

16.

Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors.

Liu TH, Oscherwitz J, Schnepp B, Jacobs J, Yu F, Cease KB, Johnson PR.

Mol Ther. 2009 Feb;17(2):373-9. doi: 10.1038/mt.2008.242. Epub 2008 Nov 11.

17.

The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer.

Zhao L, Sheldon K, Chen M, Yin MS, Hayman JA, Kalemkerian GP, Arenberg D, Lyons SE, Curtis JL, Davis M, Cease KB, Brenner D, Anscher MS, Lawrence TS, Kong FM.

Lung Cancer. 2008 Feb;59(2):232-9. Epub 2007 Oct 1.

PMID:
17905467
18.

Low-dose intraperitoneal Freund's adjuvant: toxicity and immunogenicity in mice using an immunogen targeting amyloid-beta peptide.

Oscherwitz J, Hankenson FC, Yu F, Cease KB.

Vaccine. 2006 Apr 5;24(15):3018-25. Epub 2005 Nov 8.

PMID:
16307832
19.

New insights and approaches regarding B- and T-cell epitopes in HIV vaccine design.

Oscherwitz J, Gotch FM, Cease KB, Berzofsky JA.

AIDS. 1999;13 Suppl A:S163-74. Review. No abstract available.

PMID:
10885773
20.
21.

Recovery and biological activity of filgrastim after injection through silicone rubber catheters.

McCullough JM, Sprentall-Nankervis E, Potcova CA, Cease KB.

Am J Health Syst Pharm. 1995 Jan 15;52(2):186-8.

PMID:
12879546
22.

Optimized PCR using Vent polymerase.

Cease KB, Potcova CA, Lohff CJ, Zeigler ME.

PCR Methods Appl. 1994 Apr;3(5):298-300. No abstract available.

23.

Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development.

Cease KB, Berzofsky JA.

Annu Rev Immunol. 1994;12:923-89. Review.

PMID:
7516670
24.
25.

Autologous T-cell-helper-epitope peptides modulate immunogenicity and response specificity.

Cease KB, Groeneveld LM, Probert WS.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1383. No abstract available.

PMID:
1281657
26.

Enhancement of lymphocyte proliferation assays by use of serum-free medium.

Kaldjian EP, Chen GH, Cease KB.

J Immunol Methods. 1992 Mar 4;147(2):189-95.

PMID:
1532181
27.
28.

Hsp27 is a mediator of sustained smooth muscle contraction in response to bombesin.

Bitar KN, Kaminski MS, Hailat N, Cease KB, Strahler JR.

Biochem Biophys Res Commun. 1991 Dec 31;181(3):1192-200.

29.

Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primates.

Hosmalin A, Nara PL, Zweig M, Lerche NW, Cease KB, Gard EA, Markham PD, Putney SD, Daniel MD, Desrosiers RC, et al.

J Immunol. 1991 Mar 1;146(5):1667-73.

PMID:
1704401
30.

Peptide component vaccine engineering: targeting the AIDS virus.

Cease KB.

Int Rev Immunol. 1990;7(1):85-107. Review.

PMID:
1722499
31.

Fine specificity of T cell recognition of the same peptide in association with different I-A molecules.

Brett SJ, Cease KB, Ouyang CS, Berzofsky JA.

J Immunol. 1989 Aug 1;143(3):771-9.

PMID:
2473109
32.

Identification of proteases that process distinct epitopes on the same protein.

Takahashi H, Cease KB, Berzofsky JA.

J Immunol. 1989 Apr 1;142(7):2221-9.

PMID:
2466893
33.

T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction.

Hale PM, Cease KB, Houghten RA, Ouyang C, Putney S, Javaherian K, Margalit H, Cornette JL, Spouge JL, DeLisi C, et al.

Int Immunol. 1989;1(4):409-15.

PMID:
2484961
34.

Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2.

Waldmann TA, Goldman CK, Bongiovanni KF, Sharrow SO, Davey MP, Cease KB, Greenberg SJ, Longo DL.

Blood. 1988 Nov;72(5):1805-16.

35.

Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.

Berzofsky JA, Bensussan A, Cease KB, Bourge JF, Cheynier R, Lurhuma Z, Salaün JJ, Gallo RC, Shearer GM, Zagury D.

Nature. 1988 Aug 25;334(6184):706-8.

PMID:
2457809
37.

An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.

Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette JL, DeLisi C, Moss B, Germain RN, Berzofsky JA.

Proc Natl Acad Sci U S A. 1988 May;85(9):3105-9.

38.

Limiting dilution comparison of the repertoires of high and low responder MHC-restricted T cells.

Kojima M, Cease KB, Buckenmeyer GK, Berzofsky JA.

J Exp Med. 1988 Mar 1;167(3):1100-13.

39.

Antigenic structures recognized by T cells: towards the rational design of an AIDS vaccine.

Cease KB, Berzofsky JA.

AIDS. 1988;2 Suppl 1:S95-101. Review. No abstract available.

PMID:
3147685
40.

Quantitation of T-macrophage binding avidity with and without antigen using a novel centrifugation assay.

Richardson BC, Laing TJ, Cease KB.

Immunol Invest. 1987 Nov;16(7):589-605.

PMID:
3502124
41.

Protein antigenic structures recognized by T cells: potential applications to vaccine design.

Berzofsky JA, Cease KB, Cornette JL, Spouge JL, Margalit H, Berkower IJ, Good MF, Miller LH, DeLisi C.

Immunol Rev. 1987 Aug;98:9-52. Review.

PMID:
2443443
42.

Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins.

Cornette JL, Cease KB, Margalit H, Spouge JL, Berzofsky JA, DeLisi C.

J Mol Biol. 1987 Jun 5;195(3):659-85.

PMID:
3656427
43.

Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.

Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, Fischinger PJ, Gallo RC, DeLisi C, et al.

Proc Natl Acad Sci U S A. 1987 Jun;84(12):4249-53. Erratum in: Proc Natl Acad Sci U S A 1988 Nov;85(21):8226.

44.

Prediction of immunodominant helper T cell antigenic sites from the primary sequence.

Margalit H, Spouge JL, Cornette JL, Cease KB, Delisi C, Berzofsky JA.

J Immunol. 1987 Apr 1;138(7):2213-29.

PMID:
2435793
46.

Immunologically relevant peptide antigen exists on the presenting cell in a manner accessible to macromolecules in solution.

Cease KB, Buckenmeyer G, Berkower I, York-Jolley J, Berzofsky JA.

J Exp Med. 1986 Nov 1;164(5):1440-54.

47.
48.

Cooperative clinical trials and continuing medical education.

Cease KB.

N Engl J Med. 1983 Jan 27;308(4):225. No abstract available.

PMID:
6848928

Supplemental Content

Loading ...
Support Center